$ALMS
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Healthcare
Sector
Biotechnology
Industry
Martin Babler
CEO
168
Employees
$9.80
Current Price
$2.87B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 1 | 4 | $10,726,255.17 | 986,721 | 10.58:1 |
| Sells | 1 | 2 | $1,014,028.24 | 96,131 | ||
| 2 months | Buys | 1 | 4 | $10,726,255.17 | 986,721 | 7.62:1 |
| Sells | 7 | 8 | $1,408,338.85 | 111,084 | ||
| 3 months | Buys | 1 | 4 | $10,726,255.17 | 986,721 | 6.93:1 |
| Sells | 7 | 9 | $1,548,338.85 | 116,084 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | AKKARAJU SRINIVAS Director | Purchase | 273,290 | $10.63 | $2,904,280.16 | View Details |
| Sep 8, 2026 | AKKARAJU SRINIVAS Director | Sale | 48,065 | $10.55 | $507,008.85 | View Details |
| Sep 4, 2026 | AKKARAJU SRINIVAS Director | Purchase | 220,070 | $11.17 | $2,458,842.11 | View Details |
| Sep 8, 2026 | AKKARAJU SRINIVAS Director | Purchase | 273,291 | $10.63 | $2,904,290.79 | View Details |
| Sep 8, 2026 | AKKARAJU SRINIVAS Director | Sale | 48,066 | $10.55 | $507,019.39 | View Details |
| Sep 4, 2026 | AKKARAJU SRINIVAS Director | Purchase | 220,070 | $11.17 | $2,458,842.11 | View Details |
| Aug 3, 2026 | Schroer John R. Chief Financial Officer | Sale | 3,282 | $26.37 | $86,546.34 | View Details |
| Aug 3, 2026 | Pangali Sanam Chief Legal Officer | Sale | 1,364 | $26.37 | $35,968.68 | View Details |
| Aug 3, 2026 | Hardiman Roy C. Chief Business&Strategy Ofcr | Sale | 2,692 | $26.37 | $70,988.04 | View Details |
| Aug 3, 2026 | Goldstein David M Chief Scientific Officer | Sale | 2,596 | $26.37 | $68,456.52 | View Details |
| Aug 3, 2026 | Drappa Jorn Chief Medical Officer | Sale | 2,447 | $26.37 | $64,527.39 | View Details |
| Aug 3, 2026 | Bradley Mark Christopher Chief Development Officer | Sale | 2,572 | $26.37 | $67,823.64 | View Details |
| Jul 6, 2026 | Pangali Sanam Chief Legal Officer | Sale | 5,000 | $28.00 | $140,000.00 | View Details |
36 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Related Activity
Cross-company insider connections and cluster buy signals
Cluster Buy Signals
$ALMS appeared in 2 cluster buy signals:
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: